- Datum18.09.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
stock3
Prothena Corp. PLC Aktie
Verkaufen
Kaufen
Prothena Corp. PLC Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Prothena Corp. PLC Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,96 %
Intraday
-0,24 %
1 Woche
0,85 %
1 Monat
-39,93 %
Seit Jahresbeginn
-61,99 %
1 Jahr
-71,74 %
3 Jahre
-23,28 %
5 Jahre
-86,22 %
10 Jahre
Passender Service zu Prothena Corp. PLC
Webinar zu Prothena Corp. PLC
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,320-22,710
- Jahrestief / Hoch ($)4,320-16,665
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Prothena Corp. PLC
Keine Dividenden verfügbar
Termine von Prothena Corp. PLC
- Okt30Prothena Corp. PLCQ3 2025 Earnings Release
- Feb12Prothena Corp. PLCQ4 2025 Earnings Release
- Mai13Prothena Corp. PLCQ1 2026 Earnings Release
Beschreibung
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
